Contineum Therapeutics, Inc. Class A Common Stock Market Cap ($319.37 Million)
Market Cap & Net Worth: Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Contineum Therapeutics, Inc. Class A Common Stock market cap. Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) has a market capitalization of $319.37 Million ($319.37 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14215 globally and #3414 in its home market, demonstrating a 19.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Contineum Therapeutics, Inc. Class A Common Stock's stock price $9.69 by its total outstanding shares 32958632 (32.96 Million). Also see CTNM cash flow conversion for how efficiently the company converts equity into cash flow.
Contineum Therapeutics, Inc. Class A Common Stock Market Cap History (2024–2026)
Contineum Therapeutics, Inc. Class A Common Stock market cap history from 2024 to 2026. Data shows change from $484.00 Million to $319.37 Million (-17.64% CAGR). Check Contineum Therapeutics, Inc. Class A Com (CTNM) stock price for real-time trading data and today's change.
Index Memberships
Contineum Therapeutics, Inc. Class A Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #378 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1390 of 3165 |
Weight: Contineum Therapeutics, Inc. Class A Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Contineum Therapeutics, Inc. Class A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Contineum Therapeutics, Inc. Class A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Contineum Therapeutics, Inc. Class A Com growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CTNM by Market Capitalization
Companies near Contineum Therapeutics, Inc. Class A Common Stock in the global market cap rankings as of November 4, 2026. Also see CTNM total asset value for a full breakdown of the balance sheet.
Key companies related to Contineum Therapeutics, Inc. Class A Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Contineum Therapeutics, Inc. Class A Common Stock (2024–2026)
Market capitalization of Contineum Therapeutics, Inc. Class A Common Stock from 2024 to today. Between 2024 and today, Contineum Therapeutics, Inc. Class A Common Stock's market cap moved from $484.00 Million to $ 319.37 Million, with a yearly change of -17.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $319.37 Million | -15.22% |
| 2025 | $376.72 Million | -22.17% |
| 2024 | $484.00 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Contineum Therapeutics, Inc. Class A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $319.37 Million USD |
| MoneyControl | $319.37 Million USD |
| MarketWatch | $319.37 Million USD |
| marketcap.company | $319.37 Million USD |
| Reuters | $319.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibr… Read more